Chemoimmunotherapy and Radiation in Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Locally Advanced Malignant Neoplasm
Interventions
DRUG

Tadalafil

One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.

DRUG

Gemcitabine

Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.

RADIATION

Radiation

Patients will receive 3 doses of radiation (8-10 Gy per fraction).

PROCEDURE

Pancreaticoduodenectomy

Surgical resection.

Trial Locations (1)

97213

Portland Providence Medical Center, Portland

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Providence Health & Services

OTHER

NCT01903083 - Chemoimmunotherapy and Radiation in Pancreatic Cancer | Biotech Hunter | Biotech Hunter